DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 76 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCorporate Action

Natco Pharma Limited — Rights Issue

NSE 1 hr ago·25 Sept 2026, 5:47 am

Natco Pharma

Natco Pharma has announced a rights issue to raise capital, offering shareholders the opportunity to buy additional equity shares. The company proposes to issue 2 new shares for every 21 shares currently held by investors. This rights issue will be priced at Rs. 750 per share, which includes a premium of Rs. 748.

For shareholders, this is a chance to increase their stake in the company at a discounted rate compared to the prevailing market price. The capital raised is intended to strengthen the company's balance sheet and support its future growth plans.

Investors should watch the company's future announcements regarding the timeline for the issue and the utilization of the raised funds. It is also important to monitor the market's reaction to the rights issue price.